Ti T Y, Monteiro E H, Lam S, Lee H S
Antimicrob Agents Chemother. 1985 Oct;28(4):540-3. doi: 10.1128/AAC.28.4.540.
The efficacy and safety of ceftriaxone in the treatment of bacteremic typhoid fever was studied in 14 patients. Ceftriaxone at a dosage of 50 to 60 mg/kg per day was administered intravenously in two divided doses in 13 patients and as a single dose in 1 patient. When the two patients with medical complications causing persistent fever and the patient who was febrile during therapy were excluded from the calculations, the mean period of defervescence was 4 days. Five to eight days of ceftriaxone therapy was adequate for the patients who were cured. The 14 patients treated with ceftriaxone included 13 patients who were considered cured, although 1 was a convalescent carrier, and one patient who was a treatment failure. There were no relapses in the 11 patients who were monitored for 1 to 8 months. Both peak and trough concentrations of ceftriaxone were well above the ceftriaxone MICs for the Salmonella typhi strains isolated from the patients. We have demonstrated that ceftriaxone can be used successfully in the treatment of typhoid fever in some patients. The advantages of its use include rapid clinical response, short course of treatment, and lack of serious adverse drug reactions.
对14例菌血症型伤寒热患者进行了头孢曲松治疗的疗效和安全性研究。13例患者每天以50至60mg/kg的剂量静脉注射头孢曲松，分两次给药，1例患者单次给药。在计算时排除两名因内科并发症导致持续发热的患者以及治疗期间发热的患者后，平均退热时间为4天。对于治愈的患者，5至8天的头孢曲松治疗足够。接受头孢曲松治疗的14例患者中，13例被认为治愈，尽管有1例为恢复期带菌者，1例治疗失败。在接受1至8个月监测的11例患者中无复发情况。从患者分离出的伤寒沙门菌菌株的头孢曲松峰浓度和谷浓度均远高于头孢曲松的最低抑菌浓度。我们已证明头孢曲松可成功用于部分患者的伤寒热治疗。其使用的优点包括临床反应迅速、疗程短以及无严重药物不良反应。
